MRNA Stock
Moderna, Inc. Common Stock
—
Price
Daily closes via Alpaca (IEX); today's point is the latest trade.
Key stats
Valuation
P/E (trailing)n/a
Price / sales31.3
Price / book11.2
EPS (12 mo)−$7.10
Beta1.28
Financial health last 12 months
Revenue growth+13.1%
Gross margin39.0%
Net margin-110.5%
Return on equity-37.6%
Debt / equity0.52
Hover a figure for what it means.
Analyst ratings Nov 2026 · 31 analysts
Consensus: Hold
Strong buy 3Buy 7
Hold 17Sell 3
Strong sell 1
| Month | Buy | Hold | Sell | Consensus |
|---|---|---|---|---|
| Nov 2026 | 10 | 17 | 4 | Hold |
| Oct 2026 | 11 | 16 | 4 | Hold |
| Sep 2026 | 11 | 17 | 2 | Hold |
| Aug 2026 | 9 | 18 | 3 | Hold |
Latest news
Learn Why The Bull Case For Moderna (MRNA) Could Change Following Melanoma Vaccine Trial Results
Yahoo · 1d ago
What A Cancer Vaccine Stumble Means For Moderna Stock
Yahoo · 1d ago
BUZZ Investing: AI Reassessment Drives Tech Rotation, BUZZ Index Declines
SeekingAlpha · 1d ago
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
Yahoo · 1d ago
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
Yahoo · 2d ago
Headlines from the last 10 days via Finnhub; links open the publisher's article.
Next earnings
No report scheduled in the next 4 months.
Past earnings moves
No tracked reports yet. TradeSphere saves the expected and actual move for every report from Nov 3, 2026 on, for stocks on the Earnings page.